Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCT (pressure cycling technology) to be developed for clinical diagnostics:

This article was originally published in Clinica

Executive Summary

Boston Biomedica has signed a co-operative R&D agreement with the US National Institutes of Health Clinical Center to develop clinical diagnostic applications of the company's pressure cycling technology (PCT). PCT is a new technology that uses pressure rather than temperature to control chemical reactions. The technology is claimed to lower the risk of infection among laboratory workers and provide more rapid, sensitive and accurate diagnosis. West Bridgewater, Massachusetts-based Boston Biomedica acquired the PCT technology when it purchased Bio Seq in 1998.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel